TY - JOUR
T1 - Lack of Efficacy of Interferon-α Therapy in Recurrent, Advanced Cervical Cancer
AU - Wadler, Scott
AU - Wiernik, Peter H.
AU - Wadler, Scott
AU - Burk, Robert D.
AU - Runowicz, Carolyn D.
AU - Goldberg, Gary
AU - McGill, Frances
AU - Burk, Robert D.
AU - Tachezy, Ruth
AU - Neuberg, Donna
AU - Rameau, Ronalde
AU - Comis, Robert
AU - Edmonson, John
AU - Wiernik, Peter H.
PY - 1995/12
Y1 - 1995/12
N2 - Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.
AB - Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.
UR - http://www.scopus.com/inward/record.url?scp=0029584568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029584568&partnerID=8YFLogxK
U2 - 10.1089/jir.1995.15.1011
DO - 10.1089/jir.1995.15.1011
M3 - Article
C2 - 8746781
AN - SCOPUS:0029584568
SN - 1079-9907
VL - 15
SP - 1011
EP - 1016
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 12
ER -